

Information Regarding Clinical Trial

| | |
|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Title | A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab In Combination With Chemotherapy Followed By Maintenance Therapy Of Avelumab In Combination With The Poly (Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Previously Untreated Advanced Ovarian Cancer. |
| Protocol Number | B9991030 |
| Sponsor | Pfizer |
| Investigator | J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703 |
| Study Related Phone Numbers | 479-587-1700 (24 hours) |
| Key Points for Study | Must have completed primary surgical debulking procedure or be candidates for neoadjuvant chemotherapy Must be candidates for Bevacizumab in combination with platinum based chemotherapy |